In neurodegenerative tauopathies, progressive accumulation of microtubule-associated protein tau interacts with glial-driven neuroinflammation to recruit circulating effector T cells across a compromised blood-brain barrier, transforming adaptive immunity into a critical driver of progressive neuronal death. While the central nervous system was historically viewed as an immune-privileged site, clinical and experimental evidence reviewed in Molecular Neurodegeneration Advances demonstrates that primary tauopathies including progressive supranuclear palsy, Pick’s disease, and corticobasal degeneration, alongside secondary forms like Alzheimer’s disease converge upon shared inflammatory cascades. Although innate immune activation by resident microglia and astrocytes has long been recognized as a disease hallmark, peripheral adaptive immune cells actively infiltrate diseased brain tissue following persistent innate signaling. Pathological tau hyperphosphorylation impairs degradation and triggers glial stress factors that alter vascular boundaries. This coordinated immune recruitment establishes a self-perpetuating neurotoxic environment, revealing that adaptive immune responses critically shape pathological progression rather than merely serving as passive bystanders.
The underlying biochemistry of tau protein provides the primary catalyst for this pathological neuroimmune cascade. Encoded by the MAPT gene located on human chromosome 17 and murine chromosome 11, tau physiologically binds axonal tubulin to stabilize the neuronal microtubule cytoskeleton while supporting neurogenesis, synaptic plasticity, and myelination. In the healthy adult human brain, alternative splicing of exons 2, 3, and 10 generates six distinct molecular isoforms exhibiting an approximate one-to-one ratio between three-repeat and four-repeat domain conformations. Disruptions to this stoichiometric equilibrium, alongside pathological post-translational modifications including extensive serine and threonine hyperphosphorylation within proline-rich and carboxyl-terminal domains, drastically reduce tau solubility and promote cytotoxic fibrillar aggregation. Furthermore, structural differences complicate preclinical modeling: adult mice express only four-repeat isoforms and produce a protein lacking eleven amino-terminal residues found in human tau. Mass spectrometry demonstrates selective four-repeat increases in corticobasal degeneration and progressive supranuclear palsy, underscoring how specific conformational shifts stimulate sustained neuroinflammation.
Chronic innate immune activation serves as the decisive conduit connecting localized tau aggregation to broader adaptive immune recruitment. Resident microglia and astrocytes respond to early pathological tau lesions by releasing pro-inflammatory cytokines including interleukin-1 beta, tumor necrosis factor-alpha, and type I interferons while modulating phagocytic activity. Positron emission tomography imaging using the microglial radiotracer 11C-PK11195 and the tau tracer 18F-AV1451 in patients with progressive supranuclear palsy reveals profound co-localization of microglial activation and tau accumulation across the insula, temporoparietal junction, brainstem, and cerebellum. Experimental studies confirm this mechanistic link: adoptive transfer of CX3CR1-deficient activated microglia into wild-type mice triggers endogenous tau hyperphosphorylation, whereas pharmacological microglial depletion using CSF1R inhibitors in P301S tauopathy mouse models expressing human APOE4 suppresses brain atrophy, halts hyperphosphorylated tau deposition, and prevents subsequent T cell parenchymal infiltration. These observations establish that reactive microglia are key mediators driving vascular disruption and priming central nervous system tissues for lymphocyte entry.
Reactive astrogliosis provides complementary chemotactic architecture that actively accelerates the trans-endothelial migration of effector lymphocytes into vulnerable brain regions. Distinct phenotypes characterize astrocytic involvement across primary tauopathies, illustrated by tufted astrocytes in progressive supranuclear palsy motor cortex and striatum, alongside astrocytic plaques representing early lesions in corticobasal degeneration. Activated astrocytes secrete critical chemokines, including CCL2, CCL5, and CXCL10, which are measurably elevated within the cerebrospinal fluid, plasma, and post-mortem tissue of individuals with frontotemporal lobar degeneration and Alzheimer’s disease. These released signaling molecules establish precise chemotactic gradients across the brain microvasculature: CCL2 engages CCR2 receptors to facilitate transmigration, CCL5 binds CCR5 to promote leukocyte adhesion and memory cell chemotaxis, and CXCL10 binds CXCR3 expressed on activated effector T cells to enhance directional entry. Working with border-associated macrophages monitoring perivascular spaces and choroid plexus interfaces, reactive astrocytes convert local tissue stress into systematic recruitment signals for peripheral cellular immunity.
Anatomical investigations into central nervous system surveillance demonstrate that peripheral and central compartments maintain communication through specialized meningeal and lymphatic channels. In non-inflamed human cerebrospinal fluid, flow cytometry detects predominantly CD4-positive memory-like T cells expressing CD45RA-negative, CD27-positive, and CD69-positive markers, while post-mortem corpus callosum tissue reveals localized populations of differentiated CD8-positive and CD4-positive effector cells that express CD127, CXCR1, CXCR3, CD69, and CD103 but lack CCR7 and downregulate S1PR1. These quiescent resident lymphocytes support vascular barrier integrity without provoking damaging inflammation. However, cerebrospinal fluid drainage through arachnoid cuff exit points into meningeal lymphatic vessels continuously carries central nervous system antigens into deep cervical lymph nodes, exposing peripheral dendritic cells to pathological proteins. Serum profiling in patients with progressive supranuclear palsy, frontotemporal lobar degeneration, and corticobasal degeneration confirms marked systemic immune activation, including elevations in tumor necrosis factor-alpha, interleukin-2, interleukin-6, and interleukin-17, produced primarily by helper TH17 and meningeal gamma-delta T cells.
Post-mortem histopathology and immunophenotypic mapping demonstrate prominent infiltration of conventional T lymphocytes within degenerating brain regions in primary and secondary tauopathies. Elevated CD4-positive and CD8-positive T cells infiltrate frontotemporal lobar degeneration cortices, where CD8-positive density correlates with hyperphosphorylated tau burden, mirroring patterns in progressive supranuclear palsy substantia nigra and chronic traumatic encephalopathy sulci. In advanced Alzheimer’s disease, parenchymal lymphocyte accumulation correlates tightly with Braak histopathological staging, with hippocampal infiltrates consisting of up to ninety percent CD8-positive cytotoxic T cells that correlate with tau pathology rather than amyloid-beta deposition. Parallel single-cell transcriptomic and mass spectrometry analyses of peripheral blood and cerebrospinal fluid reveal expansions of CD45RA-positive effector memory TEMRA CD8-positive cells whose frequencies correlate inversely with cognitive performance. Furthermore, clonally expanded cerebrospinal fluid CD8-positive T cells express cytolytic granzymes, NKG7, and CXCR6, whose cognate ligand CXCL16 is elevated on monocytes in cognitive impairment.
Functional evaluations utilizing preclinical mouse models reveal a complex, biphasic relationship between adaptive immunity and neurodegeneration, where therapeutic outcome depends strictly upon intervention timing. In adult Thy-tau22 transgenic mice and P301S mice co-expressing human APOE4, systemic antibody depletion of total CD3-positive or combined CD4-positive and CD8-positive subsets at symptom onset significantly reduced cerebral atrophy, attenuated microglial activation, lowered phosphorylated tau burden, and preserved spatial memory performance. Conversely, complete germline genetic deletion of CD8-positive T cells in P301S mice produced paradoxical worsening of disease, resulting in increased hyperphosphorylated tau accumulation, aggravated astrogliosis, pronounced microglial dysfunction, and accelerated axonal neurofilament light chain release. This discordance highlights mechanistic divergence between developmental deficiency and adult therapeutic depletion. While systemic antibody therapy selectively depletes circulating and newly infiltrating effector lymphocytes while sparing protective resident memory populations, constitutive germline deletion disrupts early life immune development and homeostatic surveillance, revealing that CD8-positive T cells provide early physiological protection.
At the molecular level, infiltrating cytotoxic T cells inflict tissue injury through non-canonical serine protease release and inflammatory cytokines. Single-cell sequencing and flow cytometry demonstrate that clonally expanded brain-infiltrating CD8-positive T cells express exhaustion markers including PD-1, LAG3, TIGIT, TOX, and EOMES alongside high granzyme K. Unlike classical granzyme B, granzyme K does not cleave caspases to induce apoptotic death; instead, it activates protease-activated receptor-1 to promote endothelial transmigration, stimulate cellular senescence phenotypes, induce neuronal calcium dyshomeostasis, and initiate complement activation via C3 or C4 and C2 convertase cleavage. Simultaneously, infiltrating lymphocytes secrete substantial quantities of interferon-gamma, which is elevated in P301S mouse brains and upregulates microglial MHC class II expression while directly promoting tau phosphorylation. Targeted neutralization of interferon-gamma in P301S mice co-expressing human APOE3 decreased microgliosis, reduced tau hyperphosphorylation, and attenuated neurodegeneration, confirming that lymphocyte-derived cytokines amplify destructive inflammatory cascades.
These mechanistic discoveries have spurred novel therapeutic strategies designed to remodel adaptive immune balance rather than applying indiscriminate immunosuppression across the central nervous system. Systemic depletion can produce adverse outcomes, as treating P301S mice with the sphingosine-1-phosphate receptor modulator fingolimod unexpectedly increased cerebral CD8-positive T cells and worsened neurodegeneration. Consequently, clinical translation has shifted toward harnessing regulatory T cells that express FOXP3, high-affinity CD25 interleukin-2 receptor alpha subunits, and CTLA-4 to suppress excessive effector responses. A phase II trial (NCT01988506) evaluating low-dose interleukin-2 in Alzheimer’s disease demonstrated safety and selective regulatory T cell expansion, reducing inflammatory CCL2, CCL11, and IL-15 while elevating IL-4, stabilizing plasma neurofilament light chain, and displaying positive cognitive trends.
Translating preclinical immunotherapies from rodent models to patients faces substantial immunological and chronological hurdles. Fundamental biological divergences distinguish human and murine immunity: peripheral blood in mice is dominated by circulating lymphocytes whereas human blood possesses a higher proportion of neutrophils, all murine T cells express CD28 compared to eighty percent in humans, and activated human T cells uniquely express MHC class II molecules. Furthermore, transgenic animal paradigms compress severe neurodegenerative pathology into several months through aggressive promoter-driven transgene expression, whereas human tauopathies develop over several decades, fostering distinct states of cellular senescence and exhaustion. Trials targeting broader inflammatory pathways, such as the TNF-alpha inhibitor etanercept (NCT01068353), failed in Alzheimer’s disease patients despite preclinical success, while p38-alpha kinase inhibitors like neflamapimod continue investigation. Future therapeutic success will require longitudinal human profiling to establish optimal intervention windows.
Subject of Research: Adaptive immune responses and T cell infiltration mechanisms in tauopathy progression
Article Title: Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons
Article References: Bosch, M. E., & Ulrich, J. D. (2026). Spilling the T: T cells in tauopathy mechanisms, disease progression, and therapeutic horizons. Molecular Neurodegeneration Advances, 2(1), Article 14. https://doi.org/10.1186/s44477-026-00020-5
Image Credits: AI Generated
DOI: 10.1186/s44477-026-00020-5
Keywords: tauopathies, T cell infiltration, neuroinflammation, microglia activation, astrocytic plaques, Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobar degeneration, granzyme K, regulatory T cells, interferon-gamma, blood-brain barrier, microtubule-associated protein tau, neurofilament light chain, low-dose interleukin-2, cervical lymph nodes
